Introduction
Each year in the United States, more than 50 000 new cases of bladder cancer are diagnosed, and more than 11 000 people die of this disease. 1 Although bacillus Calmette-Guerin (BCG) provides effective therapy for superficial bladder cancer, long-term failure is common. 2 Progression in stage is a serious event requiring more aggressive treatment. The prognosis for patients with advanced bladder cancer is poor despite the use of multimodal therapy, with a 5-year survival of only 20-40%. 3, 4 These data testify to the pressing need for improvements in the treatment of bladder cancer.
The identification of the PTEN gene product as a phosphatase suggested its role as a regulator of mitogenic signaling pathways. PTEN acts as a phosphatidylinositol phosphatase and appears to play a role in the phosphatidylinositol 3 0 -kinase (PI3'K) signal transduction pathway. Introduction of PTEN into cells deficient in this gene inhibits the activation of Akt, a serine-threonine kinase. 5, 6 Akt is involved in a variety of proliferative and antiapoptotic pathways that are dependent upon PI3'K signaling for activation. We previously showed that PTEN inhibits the growth of human bladder cancer cells in vitro and restores chemosensitivity to a doxorubicin-resistant human bladder cancer cell subline. 7 In the present study, we evaluated PTEN gene therapy of human bladder cancer using cell lines that differ in the PTEN pathway. UM-UC-14 cells have wild-type PTEN, UM-UC-6dox cells are doxorubicin resistant and have wild-type PTEN but exhibit increased expression of phosphorylated Akt, and UM-UC-3 cells have a deletion in PTEN and exhibit increased expression of phosphorylated Akt. We demonstrate that PTEN gene therapy of human bladder cancer cells induces apoptosis and inhibits tumor growth in vivo. This is particularly effective in cells that have genomic alterations of PTEN. Increased efficacy was observed in vivo when PTEN gene therapy and systemic doxorubicin were combined.
Results

PTEN gene therapy
UM-UC-3 cells infected with Ad-MMAC in vitro did not produce tumors in nude mice (data not shown). On the other hand, cells that were mock infected or infected with Ad-CTR grew aggressively within the same period. These data were reproducible and determined in two independent experiments.
We infected established subcutaneous UM-UC-3 and UM-UC-14 tumors in nude mice with Ad-MMAC, Ad-CTR, or mock infection. Three injections of Ad-MMAC (1.5 Â 10 10 PFU in total) into these established tumors dramatically suppressed tumor growth compared with injections of phosphate-buffered saline (PBS) or Ad-CTR (Po0.01, Figure 1 ). UM-UC-3 tumors completely disappeared in all mice treated with Ad-MMAC, whereas UM-UC-3 tumors treated with PBS or Ad-CTR continued to grow rapidly. UM-UC-14 tumors that received injections of Ad-MMAC resumed growth 30 days after treatment. Data shown were determined in two independent experiments.
The PTEN deletion in UM-UC-3 cells caused low phosphatidylinositol phosphatase activity with resultant high levels of phosphorylated Akt. These phenotypes were reversed by Ad-MMAC infection. Western analysis demonstrated increased expression of PTEN and decreased expression of phosphorylated Akt in UM-UC-3 tumors after direct injection of Ad-MMAC compared with tumors treated with Ad-CTR or PBS (Figure 2 ). Immunohistochemical analysis showed that UM-UC-3 tumors infected with Ad-MMAC expressed PTEN and exhibited decreased amounts of phosphorylated Akt, whereas tumors treated with Ad-CTR or PBS were negative for PTEN and diffusely positive for phosphorylated Akt (Figure 3 ). UM-UC-14 tumors express wildtype PTEN. Injection of Ad-MMAC did not increase PTEN expression by immunohistochemical analysis (data not shown). UM-UC-14 tumors do not express phosphorylated Akt.
Ad-MMAC injection into established UM-UC-3 tumors resulted in apoptosis in vivo. No apoptosis was seen in tumors injected with PBS or Ad-CTR. Apoptosis was documented by morphological changes and TUNELpositive cells (Figure 3) . Apoptosis was not detected in UM-UC-14 tumors treated with Ad-MMAC (data not shown).
Tumor growth depends on the development of an adequate blood supply through angiogenesis. 8, 9 Ad-MMAC infection of UM-UC-3 cells in vitro and UM-UC-3 tumors in vivo induced downregulation of Vascular endothelial growth factor (VEGF) (Figure 4a and b) . UM-UC-14 and UM-UC-6dox cells treated with Ad-MMAC did not show significant downregulation of VEGF (data not shown). Tumors infected with Ad-MMAC exhibited decreased microvessel density compared with those infected with Ad-CTR (Figure 4c and d; Po0.01). UM-UC-3 tumors exhibited the greatest decrease in microvessel density (70%) followed by UM-UC-6dox (51%) and UM-UC-14 (36%). 
PTEN gene therapy with doxorubicin
Since PTEN downregulates phosphorylated Akt and increases sensitivity to doxorubicin, we explored combination therapy with Ad-MMAC and doxorubicin in vivo. Established UM-UC-6dox and UM-UC-14 tumors were treated with three injections of Ad-MMAC and two intraperitoneal administrations of 5 mg/kg doxorubicin ( Figure 5a ). Combination therapy with Ad-MMAC and doxorubicin significantly suppressed UM-UC-6dox tumor growth compared with control treatments (Po0.01, Figure 5b ). This combined therapy completely eradicated tumors in three of 10 mice with UM-UC-6dox tumors for more than 120 days. UM-UC-14 cells treated with Ad-MMAC and doxorubicin showed more tumor suppression than did those treated with Ad-MMAC or doxorubicin alone (Figure 5c ). However, the UM-UC-14 tumors continued to grow. These data were reproducible and determined in two independent experiments.
By Western analysis, UM-UC-6dox tumors treated with Ad-MMAC exhibited downregulation of phosphorylated Akt without a significant increase in PTEN, compared with tumors treated with Ad-CTR or PBS ( Figure 6 ). This is particularly impressive because UM-UC-6dox is a cell line that is relatively resistant to adenoviral infection. Immunohistochemical analysis demonstrated that Ad-MMAC-treated UM-UC-6dox tumors focally expressed PTEN, had decreased expression of phosphorylated Akt, and increased number of TUNEL-positive cells compared with UM-UC-6dox tumors treated with Ad-CTR (Figure 7) . 
Discussion
Gene therapy is being explored for the treatment of human cancers. 10 Clinical trials of p53 gene therapy using adenoviral gene transfer are under way for various types of cancer including bladder cancer. Although alterations of the p53 gene have been detected in some bladder cancers, particularly carcinoma in situ and muscle-invasive tumors, [11] [12] not all bladder cancers exhibit an alteration in this gene. As tumor phenotypes become more accurately defined, other molecular targets may be particularly effective in the treatment of specific tumors. 13 We previously demonstrated that adenoviral introduction of PTEN into bladder cancer cell lines suppressed tumor growth in vitro and reversed resistance to doxorubicin by inhibiting the activity of Akt. 7 This report demonstrates that in vivo PTEN gene therapy is effective for some bladder cancers. 15 To our knowledge, our data provide the first evidence that PTEN gene therapy can cure an established cancer that has a gene alteration in PTEN.
VEGF promotes tumor growth by increasing angiogenesis. PTEN has been demonstrated to regulate VEGFand tumor-induced angiogenesis through the PI3 0 K signal pathway. 16, 17 We demonstrated that Ad-MMAC treatment of established UM-UC-3 tumors resulted in significant down-regulation of VEGF and decreased microvessel density. Apoptosis was observed with Ad-MMAC treatment of UM-UC-3 in vivo but not in vitro (data not shown). The antiangiogenic effect of PTEN therapy may have contributed to this phenomenon. Smaller decreases in microvessel density were seen in UM-UC-6dox, and the least effect was seen in UM-UC-14 tumors. UM-UC-6dox is doxorubicin resistant and expresses high levels of phosphorylated Akt. UM-UC-14 is wild type for PTEN and does not express phosphorylated Akt.
Direct injection of Ad-MMAC into established UM-UC-6dox and UM-UC-14 tumors resulted in significant but transient tumor suppression in vivo. Forced expression of PTEN in UM-UC-6dox tumors caused downregulation of phosphorylated Akt and increased PTEN gene therapy of bladder cancer M Tanaka and HB Grossman apoptosis in vivo. Active (phosphorylated) Akt and its downstream targets are thought to be associated with the development of drug resistance. [18] [19] [20] Transfection of the Akt gene in the TC-32 Ewing sarcoma cell line decreases doxorubicin cytotoxicity. 21 We previously demonstrated that combined therapy with Ad-MMAC and doxorubicin enhanced the suppression of bladder cancer cell growth in vitro. 7 When this combination was used to treat established UM-UC-6dox tumors, significant tumor regression was seen, with three of 10 mice remaining tumor free for more than 120 days. However, only transient growth suppression occurred in UM-UC-14 tumors treated with combination therapy. This difference in efficacy is related to the phenotype of these two cell lines. UM-UC-6dox has decreased expression of PTEN and increased phosphorylated Akt, while UM-UC-14 has wild-type PTEN and low expression of phosphorylated Akt. Moreover, others have demonstrated that combining PTEN gene therapy with antineoplastic agents such as vincristine, cisplatin, paclitaxel, and etopside results in increased efficacy. 18, [22] [23] [24] Failure of chemotherapy due to the development of drug-resistant tumors is a significant clinical problem. 25 In bladder cancer, gene alterations at chromosome 10q including the PTEN locus appear to be associated with cancer progression. [26] [27] [28] [29] Our data demonstrate that inactivating a specific target such as phosphorylated Akt with gene therapy combined with chemotherapy can provide effective treatment for drug-resistant cancers such as UM-UC-6dox. Although doxorubicin worked well in our bladder cancer model, it is likely that other drugs would also be effective in combination with PTEN gene therapy in other tumor types. The critical issue that will enable such therapy in man is the development of an effective and safe delivery system. PTEN inhibits the activation of Akt, a serine-threonine kinase involved in proliferative and antiapoptotic pathways, and has tumor suppressive properties. This report demonstrates for the first time that forced expression of PTEN can provide effective therapy for bladder cancers with an appropriate phenotype. PTEN gene therapy demonstrated complete tumor suppression of established tumors that have deletions in this gene. Furthermore, PTEN gene therapy plus chemotherapy provided effective treatment for tumors that express phosphorylated Akt.
Materials and methods
Cell lines and adenovirus vectors
The human bladder cancer cell lines UM-UC-3 30 and UM-UC-14 31 and 293 embryonic kidney cells (obtained from American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum at 371C in an atmosphere of 5% CO 2 . UM-UC-3 has deletions from exons 3 to 9 in PTEN, and UM-UC-14 is wild type for PTEN. 7 UM-UC-6dox, a doxorubicin-VEGF resistant subline of UM-UC-6 selected in vitro by exposure to doxorubicin, was maintained in the same medium with the addition of 1 mg/dl doxorubicin. 32 The UM-UC-6dox cell line has decreased expression of PTEN and expresses phosphorylated Akt. 7 A recombinant adenovirus containing wild-type PTEN (Ad-MMAC) and a control adenovirus vector (Ad-CTR) without a transgene were used as described previously. 7 Viruses were grown in 293 cells and purified using cesium chloride density gradient ultracentrifugation. The titration of recombinant adenovirus was determined by plaque assay as described previously. 33 One plaque forming unit (PFU) equals 1 multiplicity of infection (MOI).
Western analysis
Tumors treated with Ad-MMAC, Ad-CTR, or PBS were harvested from nude mice after two direct injections of virus or PBS, and the tumors were minced, homogenized, and prepared as described previously. 34 Western analysis was performed as previously described using a rabbit polyclonal antibody to total-and phospho-Akt (Ser473) (New England Biolabs, Boston, MA, USA), a mouse monoclonal antibody to PTEN, and a rabbit polyclonal antibody to VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 7 
Animal studies
The mice were maintained and all animal experiments were conducted according to institutional guidelines established for the Animal Core Facility at The University of Texas MD Anderson Cancer Center. To examine the effect of PTEN on the tumorigenicity of )¼A Â B 2 Â 0.5236, where A is the largest dimension and B is the perpendicular diameter, as described previously. 35 To examine the effect of PTEN on established tumors, UM-UC-3 and UM-UC-14 cells were injected subcutaneously into nude mice. When the tumors reached approximately 5 mm in diameter (1 week after injection), the animals received an intratumoral injection (100 ml) of Ad-MMAC, Ad-CTR, or PBS three times (days 7, 8, and 14) for a total dose of 1.5 Â 10 10 PFU/tumor. The tumor size was measured and tumor volume calculated as described above.
Combination therapy with Ad-MMAC and doxorubicin was tested in vivo on established tumors. Subcutaneous UM-UC-6dox and UM-UC-14 tumors were treated with three injections of Ad-MMAC and two intraperitoneal administrations of 5 mg/kg doxorubicin. Controls included intratumoral PBS and intraperitoneal saline, intratumoral PBS and intraperitoneal doxorubicin, intratumoral Ad-CTR and intraperitoneal doxorubicin, and intratumoral Ad-MMAC and intraperitoneal PBS. The tumor volume was calculated as described above.
In vivo immunohistochemistry and apoptosis analysis
To evaluate apoptosis, the tumor (or, if no tumor was evident, the injection site) was removed 2 days after the second and third injection of virus vectors and embedded in paraffin blocks. For terminal deoxynucleotidyl transferase-mediated dUTP end labeling (TUNEL) assays, the tissue sections were evaluated with the TACS Á XL TM in situ apoptosis detection kit (R&D Systems, Minneapolis, MN, USA). For PTEN, phosphorylated Akt, and VEGF immunohistochemistry, antigen retrieval was first performed by incubating the slides in Target Retrieval Solution (Dako, Carpinteria, CA, USA) at 1001C in a steam bath for 20 min. Immunoperoxidase staining was performed using the Vectastatin Elite ABC kit (Vector Laboratories, Inc., Burlingame, CA, USA) with monoclonal mouse anti-PTEN (Zymed, San Francisco, CA, USA), polyclonal rabbit antiphospho-Akt (Ser473) (New England Biolabs, Boston, MA, USA), and polyclonal rabbit anti-VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Microvessel density was examined in frozen tumor sections stained with monoclonal anti-mouse CD31 (PharMingen, San Diego, CA, USA) as previously described. 36, 37 Briefly, the number of CD 31-positive microvessels were counted from tumor sections at Â 100 magnification. 38 A total of 10 fields were chosen randomly from an area of injection in each tumor.
Statistical analyses
Differences between the groups were statistically evaluated using the unpaired Student's t-test. The results are presented as means 7s.d. All P values were two-tailed, and a P value of less than 0.05 was considered to be statistically significant.
